Tag: #Global Trends

Ray Therapeutics has reached a pivotal regulatory milestone as its lead candidate, RTx-015, was granted Priority Medicines (PRIME) designation by... Read more

Bristol Myers Squibb (BMS) is generating investor buzz with its late-stage pipeline despite a modest Q1 2026 financial performance. The... Read more

Eli Lilly started the 2026 fiscal year with record-breaking numbers, driven by surging demand for its obesity and diabetes portfolio.... Read more

The biotech sector's financial momentum continues to accelerate as Hemab Therapeutics and Seaport Therapeutics made their Wall Street debuts in... Read more

Three years after navigating the Humira patent cliff, AbbVie CEO Robert Michael declares the company's position is "stronger than ever."... Read more

Boehringer Ingelheim has released topline data from its Synchronize-1 phase 3 study, revealing that its drug candidate survodutide led to... Read more

Eli Lilly has forged a major partnership with Profluent to develop advanced gene-editing tools using artificial intelligence, aiming to address... Read more

Merck KGaA has entered into a collaborative agreement with Remepy to develop integrated "hybrid drugs" that merge pharmacological treatments with... Read more

A milestone in automated autologous CAR-T production Cellares and Cabaletta Bio have formalized a 10-year commercial supply agreement, marking a... Read more